DEA’s 2026 telemedicine flexibility for prescribing controlled substances runs through December 31, 2026 under its fourth temporary extension, while Medicare’s general telehealth flexibilities run through December 31, 2027. Medicare’s separate mental health in-person provision changes on January 1, 2028.
Key Takeaways
- DEA’s temporary exception permits prescribing without a prior in-person evaluation, subject to other federal and state law.
- The Special Registration rulemaking lists November 2026 as a forecast for final action, not a confirmed effective date.
- Medicare coverage extensions and DEA prescribing flexibility have separate legal authorities and separate deadlines.
Different deadlines for DEA prescribing and Medicare coverage
Start your review by separating prescribing authority from coverage. The DEA extension concerns controlled substance prescribing without a prior in-person medical evaluation. Medicare’s provisions address telehealth coverage conditions, including geographic restrictions, eligible practitioner types and audio-only services.
A prescribing exception is not a coverage extension. These documents answer different questions, even when your team is considering the same appointment. Label each deadline with the authority and provision it belongs to before using it in a planning discussion.
| Provision or action | Date | What the source establishes |
|---|---|---|
| DEA fourth temporary extension | December 31, 2026 | Last day of the rule’s stated effective period. |
| Special Registration final action | November 2026 | Unified Agenda forecast, without a specific day. |
| Medicare general telehealth flexibilities | December 31, 2027 | Extended endpoint under Section 6209. |
| Medicare mental health in-person provision | January 1, 2028 | Revised applicability date under Section 6209(d). |
This account reflects the rules and agenda information checked as of September 27, 2026. For a later operational decision, have counsel or the relevant regulator confirm whether subsequent action has changed the position.
What the fourth temporary extension covers
DEA and the Department of Health and Human Services issued the fourth extension together. Published December 31, 2025, Federal Register document 2025-24123 gives an effective period from January 1, 2026 through December 31, 2026. That period belongs to the temporary prescribing rule.
The rule’s background explains the Ryan Haight Act framework. Subject to exceptions, a practitioner prescribing controlled substances remotely must first conduct an in-person medical evaluation within the practitioner-patient relationship. The extended exception lets a DEA-registered practitioner prescribe through telemedicine without first conducting that evaluation.
The temporary flexibility concerns the prior in-person evaluation. It remains subject to other relevant federal and state laws. Reading the extension as permission detached from those conditions would go beyond what the rule says.
For your organization’s review, identify the specific prescribing arrangement and the authority being relied on. Bring questions about applicable federal and state requirements to counsel or regulators. The federal extension alone does not resolve which additional requirements apply to your particular case.
Keep the wording narrow in internal summaries: the stated effective period of this temporary exception ends December 31, 2026. Do not turn that statement into a prediction about every telemedicine prescription after that date. The question for a later review is which authority then applies.
Why the Special Registration forecast is not an effective date
The permanent rulemaking is titled Special Registrations for Telemedicine and Limited State Telemedicine Registrations, identified as RIN 1117-AB40. The OMB/OIRA Unified Agenda lists it in Final Rule Stage. Its timetable forecasts final action in November 2026 without specifying a day.
A forecast describes expected action, not an operative requirement. The agenda entry does not establish a replacement rule’s effective date. Treat the November entry as a reason to monitor the proceeding, rather than an assurance that a replacement will apply before the temporary extension ends.
The proposed rule was published January 17, 2025. It proposed a Special Registration framework for telemedicine prescribing without a prior in-person evaluation, alongside prescription, recordkeeping and reporting requirements. Those are features of a proposal, not a description of settled replacement obligations.
The agenda says DEA is reviewing public comments and considering alternatives while drafting a final rule. Your planning documents should preserve that distinction. A useful question for counsel is what a published final text would change for your arrangements, once that text and its dates are available.
For a vendor discussion, use Vendor SLA Promises That Do Not Match Clinical Reality as a companion reading topic. Ask the vendor to identify the published authority behind any claim that its workflow supports future prescribing requirements.
Medicare’s longer extension and separate mental health date
Section 6209 of the Consolidated Appropriations Act, 2026 extended Medicare telehealth provisions separately. This is Public Law 119-75, approved February 3, 2026. Its general telehealth extensions run through December 31, 2027.
Those provisions include geographic and originating-site flexibility, expanded eligible practitioner types and audio-only telehealth. They concern Medicare coverage conditions. They do not move the stated endpoint of DEA’s fourth temporary prescribing extension to December 31, 2027.
The mental health provision needs its own entry in your review. Section 6209(d) delays Medicare’s mental-health-specific telehealth in-person requirements to January 1, 2028. That applicability date differs from the December 31, 2027 endpoint for the general Medicare flexibilities.
Use the provision’s full name when discussing an in-person requirement. The Medicare mental health provision and the DEA prescribing exception concern distinct legal requirements. A statement that an in-person requirement was delayed is incomplete unless you specify which requirement it describes.
Questions to ask before changing your workflow
For an internal review, keep the rule, the forecast and the coverage provisions in separate entries. Record the document, the relevant provision and the date associated with it. Ask counsel to assess your specific case against the applicable authorities.
Consider reviewing where your scheduling materials mention telehealth deadlines or prior in-person evaluations. For workflow discussions, pair that review with Telehealth Triage Bot Escalation Gaps: The Hidden Design Cost of Safe Handoffs. Keep questions about handoff design distinct from questions about the legal basis for prescribing.
Before adopting a later deadline, request the primary document that supports it. For Special Registration, distinguish a forecast, a published final rule and the effective date stated in that rule. Refer unresolved questions to counsel or the responsible regulator before applying an interpretation to your organization.
Frequently Asked Questions
When does the current DEA telemedicine prescribing flexibility expire?
The fourth temporary extension runs through December 31, 2026. Published December 31, 2025, it states an effective period beginning January 1, 2026.
Is a permanent replacement confirmed before that deadline?
The Unified Agenda lists Special Registration in Final Rule Stage and forecasts final action in November 2026. That forecast does not confirm a replacement’s effective date.
Does Medicare telehealth coverage expire with the DEA extension?
No. Section 6209 of Public Law 119-75 separately extends Medicare’s general telehealth flexibilities through December 31, 2027. The DEA temporary extension runs through December 31, 2026.
Does Medicare’s mental health in-person provision use the same deadline?
No. Section 6209(d) sets January 1, 2028 for the mental-health-specific in-person provision. The general Medicare telehealth flexibilities instead run through December 31, 2027.
Sources
- Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications: document record, Federal Register, DEA/HHS, December 31, 2025.
- Fourth Temporary Extension: full rule text, Federal Register, DEA/HHS, December 31, 2025.
- Special Registrations for Telemedicine and Limited State Telemedicine Registrations, RIN 1117-AB40, OMB/OIRA Unified Agenda, accessed September 27, 2026.
- Consolidated Appropriations Act, 2026, Section 6209, U.S. Government Publishing Office, approved February 3, 2026.
This article is for general information and is not legal, regulatory or medical advice.